Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib early metabolic response and pharmacokinetics study in soft tissue sarcoma
NL-OMON41252Phase 4Recruiting
- Sponsor
- Medische Oncologie
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pazopanib in soft tissue sarcoma (STS), sponsored by Medische Oncologie. Primary endpoints: Progression-free survival by early metabolic response and Effect of age on pazopanib exposure. Started Dec 2013; status: recruiting.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON41252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41252.